There should be no ESKAPE for febrile neutropenic cancer patients: The dearth of effective antibacterial drugs threatens anticancer efficacy

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 3, 2013, Pages 492-495

  Bow, E J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Manitoba Blood and Marrow Transplant Program   (Canada)

Author keywords

Carbapenemase; Extended spectrum lactamase; Gram negative bacilli; Gram positive cocci; MRSA; Multi drug resistance; VISA

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; AVIBACTAM; CEFTAROLINE; CEFTOBIPROLE; CETHROMYCIN; DELAFLOXACIN; ERAVACYCLINE; NEMONOXACIN; OMADACYCLINE; PLAZOMICIN; RADEZOLID; SOLITHROMYCIN; TEDIZOLID; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; CANCER PATIENT; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENTEROBACTER; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEBRILE NEUTROPENIA; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HEALTHCARE ASSOCIATED INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; MULTIDRUG RESISTANCE; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; SYSTEMIC THERAPY;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; NEOPLASMS; NEUTROPENIA; TREATMENT FAILURE;

EID: 84873584994     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks512     Document Type: Article

References (50)

1. Flowers C, Seidenfeld J, Bow EJ et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2012; in press.
2. Morris PG, Hassan T, McNamara M et al. Emergence of MRSA in positive blood cultures from patients with febrile neutropenia-a cause for concern. Support Care Cancer 2008; 16: 1085-8.
3. Peacock JE, Herrington DA, Wade JC et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial. Ann Intern Med 2002; 137: 77-87.
4. Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005; 40 Suppl 4: S240-S245.
5. Toussaint E, Bahel-Ball E, Vekemans M et al. Causes of fever in cancer patients (prospective study over 477 episodes). Support Care Cancer 2006; 14: 763-9.
6. Vidal L, Paul M, Ben dor I et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother 2004; 54: 29-37.
7. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
8. Spellberg B, Guidos R, Gilbert D et al. The epidemic of antibioticresistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 155-64.
9. Tleyjeh IM, Tlaygeh HM, Hejal R et al. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2006; 42: 788-97.
10. Shlaes DM, Spellberg B. Overcoming the challenges to developing new antibiotics. Curr Opin Pharmacol 2012; 12: 522-6.
11. Charles PG, Ward PB, Johnson PD et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38: 448-51.
12. Miller MA, Hyland M, Ofner-Agostini M et al. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002; 23: 137-40.
13. Vydra J, Shanley RM, George I et al. Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012; 55: 764-70.
14. Falagas ME, Vardakas KZ, Samonis G. Decreasing the incidence and impact of infections in neutropenic patients: evidence from metaanalyses of randomized controlled trials. Curr Med Res Opin 2008; 24: 215-35.
15. Falagas ME, Karageorgopoulos DE. Extended-spectrum b-lactamaseproducing organisms. J Hosp Infect 2009; 73: 345-54.
16. Walsh TR, Weeks J, Livermore DM et al. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011; 11: 355-62.
17. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008; 197: 1079-81.
18. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597-602.
19. Poirel L, Hombrouck-Alet C, Freneaux C et al. Global spread of New Delhi metallo-b-lactamase 1. Lancet Infect Dis 2010; 10: 832.
20. Poirel L, Herve V, Hombrouck-Alet C et al. Long-term carriage of NDM-1-producing Escherichia coli. J Antimicrob Chemother 2011; 66: 2185-6.
21. Walsh TR, Toleman MA. The emergence of pan-resistant Gramnegative pathogens merits a rapid global political response. J Antimicrob Chemother 2012; 67: 1-3.
22. Taur Y, Xavier JB, Lipuma L et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2012; 55: 905-14.
23. Blijlevens NM, Donnelly JP, De Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 2000; 25: 1269-78.
24. Bow EJ, Louie TJ. Changes in endogenous microflora among febrile granulocytopenic patients receiving empiric antibiotic therapy: implications for fungal superinfection. CMAJ 1987; 137: 397-403.
25. Bow EJ, Meddings JB. Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Leukemia 2006; 20: 2087-92.
26. Miyakis S, Pefanis A, Tsakris A. The challenges of antimicrobial drug resistance in Greece. Clin Infect Dis 2011; 53: 177-84.
27. Friedman CR, Whitney CG. It's time for a change in practice: reducing antibiotic use can alter antibiotic resistance. J Infect Dis 2008; 197: 1082-3.
28. Gudiol C, Calatayud L, Garcia-Vidal C et al. Bacteraemia due to extended-spectrum b-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 2010; 65: 333-41.
29. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum b-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60: 913-20.
30. Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200.
31. Quilty S, Kwok G, Hajkowicz K et al. High incidence of methicillinresistant Staphylococcus aureus sepsis and death in patients with febrile neutropenia at Royal Darwin Hospital. Intern Med J 2009; 39: 557-9.
32. Fernandez De Gatta Mdel M, Santos Buelga D, Sanchez Navarro A et al. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis. Clin Pharmacokinet 2009; 48: 273-80.
33. Kang CI, Chung DR, Ko KS et al. Risk factors for infection and treatment outcome of extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 2012; 91: 115-21.
34. Satlin MJ, Calfee DP, Chen L et al. Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma 2012; doi:10.3109/10428194.2012.723210.
35. Samonis G, Koutsounaki E, Karageorgopoulos DE et al. Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study. Eur J Clin Microbiol Infect Dis 2012; 31: 1389-98.
36. Kumar A, Ellis P, Arabi Y et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136: 1237-48.
37. Vergis EN, Hayden MK, Chow JW et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study. Ann Intern Med 2001; 135: 484-92.
38. Schramm GE, Johnson JA, Doherty JA et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 2006; 34: 2069-74.
39. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42 Suppl 2: S82-9.
40. Emerson CB, Eyzaguirre LM, Albrecht JS et al. Healthcare-associated infection and hospital readmission. Infect Control Hosp Epidemiol 2012; 33: 539-44.
41. IDSA. The 10×'20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50: 1081-3.
42. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003; 6: 427-30.
43. Informatics IIfH. The Global Use of Medicines: Outlook through 2016. http://www.imshealth.com/ims/Global/Content/Insights/IMS Institute for Healthcare Informatics/Global Use of Meds 2011/Medicines_ Outlook_Through_2016_Report (1 November 2012, date last accessed).
44. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011; 24: 71-109.
45. Patel G, Huprikar S, Factor SH et al. Outcomes of carbapenemresistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29: 1099-106.
46. Borer A, Saidel-Odes L, Riesenberg K et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009; 30: 972-6.
47. Bush K. Improving known classes of antibiotics: an optimistic approach for the future. Curr Opin Pharmacol 2012; 12: 527-34.
48. Bush K, Courvalin P, Dantas G et al. Tackling antibiotic resistance. Nat Rev Microbiol 2011; 9: 894-6.
49. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151-85.
50. Infectious Diseases Society of America. Promoting Anti-infective Development and Antimicrobial Stewardship through the U.S. Food and Drug Administration Prescription Drug User Fee Act (PDUFA) Reauthorization: Before the House Committee on Energy and Commerce's Subcommittee on Health. http://www.tufts.edu/med/apua/index_363_ 626155726.pdf (2 November 2012, date last accessed).